Access the June 17 ISCT Webinar on 'The End of the FDA Enforcement Discretion Period and its Implications'

By Felix Grignon posted 06-21-2021 15:11

The end of the FDA Enforcement Discretion Period for certain human cell, tissue, and tissue-based products (HCT/Ps), including regenerative medicine therapies, marks a new chapter in the regulation of stem cell clinics in the United States.

The objective of this webinar is to provide public information that a) summarizes the three years of the FDA Enforcement Discretion Period and reviews its impact on clinics and the market, and b) fosters a discussion among attending and impacted stakeholders on initiatives and strategies to be pursued post Enforcement Discretion Period.

The webinar took place on June 17, 2021 and a recording is accessible through the following link: